<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419692</url>
  </required_header>
  <id_info>
    <org_study_id>ROR106470</org_study_id>
    <nct_id>NCT00419692</nct_id>
  </id_info>
  <brief_title>Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food</brief_title>
  <official_title>An Open Label, Repeat Dose, Dose Escalation Study Conducted in RLS Patients to Characterize Pharmacokinetics and Food Effect of Ropinirole Controlled Release for RLS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study in RLS patients is designed to assess the affect food has on the absorption,
      distribution, metabolism and excretion of ropinirole (by dosing some patients in the fasted
      state and other patients following a high-fat breakfast), and to assess the difference in
      absorption, distribution, metabolism and excretion of ropinirole if patients are given two
      3mg ropinirole tablets versus one 6mg tablet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2006</start_date>
  <completion_date type="Actual">December 12, 2006</completion_date>
  <primary_completion_date type="Actual">December 12, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ropinirole AUC (area under the plasma concentration-time curve) over the dosing interval Ropinirole maximum plasma concentration</measure>
    <time_frame>dosing interval</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to attain the maximum plasma concentration Time taken for ropinirole concentration to fall to half initial value Incidence of adverse events Vital signs, ECG and clinical laboratory data As above, but for ropinirole metabolites</measure>
    <time_frame>Time taken for ropinirole concentration to fall to half initial value</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>Sequence WAXBYZCDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and E: 2 x 3 mg CR-RLS (fasted).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence WAXBYZCED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), E: 2 x 3 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence WAXBYZDCE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), C: 1 x 6 mg CR-RLS (fasted) and E: 2 x 3 mg CR-RLS (fasted).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence WAXBYZDEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), E: 2 x 3 mg CR-RLS (fasted) and C: 1 x 6 mg CR-RLS (fasted).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence WAXBYZECD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted),C: 1 x 6 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence WAXBYZEDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and C: 1 x 6 mg CR-RLS (fasted).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropinirole</intervention_name>
    <description>Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.</description>
    <arm_group_label>Sequence WAXBYZECD</arm_group_label>
    <arm_group_label>Sequence WAXBYZCDE</arm_group_label>
    <arm_group_label>Sequence WAXBYZDEC</arm_group_label>
    <arm_group_label>Sequence WAXBYZDCE</arm_group_label>
    <arm_group_label>Sequence WAXBYZCED</arm_group_label>
    <arm_group_label>Sequence WAXBYZEDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with a diagnosis of RLS

          -  Body mass index of 18 to 32 kg/mÂ², with a body weight of at least 50 kg

          -  Normal blood pressure pre-study

          -  Light smokers only (&lt;20/day)

        Exclusion criteria:

          -  History of postural hypotension or faints

          -  Secondary RLS

          -  Patients who suffer from a primary sleep disorder other than RLS

          -  Patients diagnosed with movement disorders

          -  Patients with unstable medical conditions

          -  Patients with personal or family history of adverse reactions or hypersensitivity to
             the study drug

          -  Patients with abnormal laboratory values

          -  Patients with hepatitis or HIV

          -  Patients who abuse alcohol or drugs

          -  Patients taking the following medications: dopamine agonists (including ropinirole),
             dopamine antagonists (e.g., metoclopramide and domperidone), levodopa/carbidopa
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>George</city>
        <zip>6530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/ROR106470?search=study&amp;search_terms=ROR106470#rs</url>
    <description>Results for study ROR106470 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2007</study_first_submitted>
  <study_first_submitted_qc>January 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2007</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetic,</keyword>
  <keyword>RLS</keyword>
  <keyword>formulation,</keyword>
  <keyword>food effect,</keyword>
  <keyword>controlled release for RLS,</keyword>
  <keyword>SK&amp;F101468,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropinirole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

